The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.
December 25th 2023
Our most-read content that featured lung cancer included articles on non–small cell lung cancer, how navigation programs can increase screening rates, and a potential link between antidepressants and lung cancer risk.
December 14th 2023
Dr Ticiana Leal: A Lot of Work Is Needed Regarding Early Detection in Lung Cancer
October 7th 2022Lung cancer screening rates remain low nationwide, and there is a need to better educate patients and clinicians about the importance of screening, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Watch
Most Patients in China With Lung Cancer Experience Financial Toxicity
October 3rd 2022A new report finds despite reforms to the country’s health care system, many patients in China with lung cancer experience stress, and sometimes health consequences, on account of the disease’s financial burden.
Read More
Expensive Targeted Lung Cancer Therapies Need to Be Tailored to the Right Patient
September 29th 2022Targeted therapies have improved outcomes for patients with lung cancer, but the goal needs to be tailoring the right therapy to the right patient, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Watch
Dr Hatim Husain Discusses HER2, Novel Therapy Exploration in Lung Cancer
September 23rd 2022During the Quality Cancer Care Alliance Summer 2022 National Leadership Summit, Hatim Husain, MD, discusses how HER2 exploration in lung cancer differs from that in breast cancer, as well as novel therapies being explored for HER2 and other disease targets.
Watch
Phase 3 Trial Backs First-line Use of Cemiplimab With Chemotherapy in aNSCLC
September 21st 2022With these new findings coming from the EMPOWER-Lung 3 trial, the anti-programmed cell death-1 inhibitor cemiplimab is now just the second of its kind to show efficacy in these patients as both monotherapy and as a combination regimen, regardless of histology.
Read More
Real-world Lung Cancer Testing Rates Are Lower Than They Should Be, Says Dr Ticiana Leal
September 14th 2022Biomarker testing should be done on all patients with an initial diagnosis of advanced nonsquamous non–small cell lung cancer, but the testing rates in the real world are lower than they should be, particularly for underserved or minority populations, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Read More
Recommendations to Safeguard Quality Shared Decision-Making for Lung Cancer Screening
September 8th 2022An updated national coverage determination from CMS about lung cancer screening has some stakeholders concerned that the quality of decision-making tools used by providers and patients may weaken.
Read More
Dr Hatim Husain: Biomarker Testing Is a Treatment Cornerstone in NSCLC
August 29th 2022Hatim Husain, MD, associate professor in the Department of Medicine at UC San Diego, discuses must-haves for successful biomarker testing in lung cancer—in particular, non–small cell lung cancer (NSCLC)—and how the field is adapting to the targeted treatment needs of its patients.
Watch
Clinicians Slow to Adopt PD-1, PD-L1 Inhibitors in NSCLC
August 23rd 2022A significant subset of patients continues to receive chemotherapy monotherapy despite the availability of newer approaches, including programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors.
Read More
HER2m NSCLC an “Exciting Area of Active Investigation,” Says Dr Ticiana Leal
August 17th 2022Results from DESTINY-Lung01 have shown promising progression-free survival and overall survival with ongoing research that may lead to a future FDA approval in non–small cell lung cancer (NSCLC), said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Watch